Free tool
FAERS Monitor: Anectine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 008453 or its brand name (Anectine, Succinylcholine Chloride). Reports on generic versions are filed under their own applications.
Reports
2,145
Serious
1,809
84% of reports
Hospitalization
734
Death reported
252
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective249
- hypotension184
- cardiac arrest164
- anaphylactic shock147
- drug interaction127
- renal failure118
- pain114
- anaphylactic reaction112
- renal impairment106
- anxiety102
- injury101
- hyperthermia malignant98
- unevaluable event93
- maternal exposure during pregnancy91
- emotional distress88
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 93 |
| 2005 | 32 |
| 2006 | 44 |
| 2007 | 51 |
| 2008 | 53 |
| 2009 | 58 |
| 2010 | 74 |
| 2011 | 208 |
| 2012 | 96 |
| 2013 | 32 |
| 2014 | 25 |
| 2015 | 57 |
| 2016 | 74 |
| 2017 | 94 |
| 2018 | 92 |
| 2019 | 158 |
| 2020 | 156 |
| 2021 | 133 |
| 2022 | 131 |
| 2023 | 125 |
| 2024 | 106 |
| 2025 | 162 |
| 2026 | 91 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,014 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperthermia malignantSignal | 98 | 691.5 | 565.9 | 62,481 |
| anaphylactic shockSignal | 147 | 56.2 | 48.1 | 7,885 |
| anaphylactic reactionSignal | 112 | 19.9 | 16.6 | 1,994 |
| cardiac arrestSignal | 164 | 19.5 | 16.8 | 2,868 |
| injurySignal | 101 | 14.1 | 11.7 | 1,219 |
| renal impairmentSignal | 106 | 12.4 | 10.3 | 1,101 |
| unevaluable eventSignal | 93 | 12.1 | 9.9 | 935 |
| maternal exposure during pregnancySignal | 91 | 10.0 | 8.2 | 732 |
| hypotensionSignal | 184 | 9.0 | 7.8 | 1,312 |
| renal failureSignal | 118 | 8.7 | 7.3 | 803 |
| drug interactionSignal | 127 | 7.9 | 6.6 | 758 |
| emotional distressSignal | 88 | 7.1 | 5.8 | 460 |
| anxietySignal | 102 | 3.5 | 2.9 | 183 |
| drug ineffective | 249 | 1.9 | 1.6 | 103 |
| pain | 114 | 1.8 | 1.5 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.